OBJECTIVES: Recent studies show that measuring pharmacodynamic (PD) effects offers a unique possibility to predict immunosuppression. Thus, in this study we have monitored the PD properties of immunosuppressants on diverse T-cell functions in heart transplant (HTx) recipients. MATERIALS: PDs and blood concentrations (PK) of three different basis-immunosuppressive drugs were studied: cyclosporin A (CsA); tacrolimus (TRL) and sirolimus (SRL). T-cell function was analysed by expression of proliferating cell nuclear antigen (PCNA) labelling, expression of cytokines (IL-2, IFN-gamma) and surface antigen (for example, CD25) by FACS analysis. RESULTS: In group I, at time points C0 and C2, increased CsA-PK significantly inhibited expression of IL-2, IFN-gamma, PCNA and CD25 (P < 0.05). Correlations (r(2)) at C2 between inhibition of T-cell functions (PD) with PK and with drug doses were: CsA-PK: 0.71-0.91 and CsA-dose: 0.73-0.87. In group II, increased TRL-PK over time did not further inhibit expression of CD25, but inhibited PCNA expression more on day 3, and IL-2 and IFN-gamma expression was significantly higher on days 2 and 3 compared to PD effects of CsA (P < 0.05). Blood SRL concentrations in C0 group III, increased on day 1 and remained stable at days 3 and 4. Expression of PCNA was not altered in the SRL-PK category, whereas expression of CD25 was higher and expression of cytokines was lower than PD effects of CsA. CONCLUSIONS: Our results show that PD effects on T-cell function can be used to monitor immunosuppression bringing potential to increase the efficacy and safety of immunosuppressive therapy after HTx.
OBJECTIVES: Recent studies show that measuring pharmacodynamic (PD) effects offers a unique possibility to predict immunosuppression. Thus, in this study we have monitored the PD properties of immunosuppressants on diverse T-cell functions in heart transplant (HTx) recipients. MATERIALS: PDs and blood concentrations (PK) of three different basis-immunosuppressive drugs were studied: cyclosporin A (CsA); tacrolimus (TRL) and sirolimus (SRL). T-cell function was analysed by expression of proliferating cell nuclear antigen (PCNA) labelling, expression of cytokines (IL-2, IFN-gamma) and surface antigen (for example, CD25) by FACS analysis. RESULTS: In group I, at time points C0 and C2, increased CsA-PK significantly inhibited expression of IL-2, IFN-gamma, PCNA and CD25 (P < 0.05). Correlations (r(2)) at C2 between inhibition of T-cell functions (PD) with PK and with drug doses were: CsA-PK: 0.71-0.91 and CsA-dose: 0.73-0.87. In group II, increased TRL-PK over time did not further inhibit expression of CD25, but inhibited PCNA expression more on day 3, and IL-2 and IFN-gamma expression was significantly higher on days 2 and 3 compared to PD effects of CsA (P < 0.05). Blood SRL concentrations in C0 group III, increased on day 1 and remained stable at days 3 and 4. Expression of PCNA was not altered in the SRL-PK category, whereas expression of CD25 was higher and expression of cytokines was lower than PD effects of CsA. CONCLUSIONS: Our results show that PD effects on T-cell function can be used to monitor immunosuppression bringing potential to increase the efficacy and safety of immunosuppressive therapy after HTx.
Authors: A P van den Berg; W N Twilhaar; G Mesander; W J van Son; W van der Bij; I J Klompmaker; M J Slooff; T H The; L H de Leij Journal: Transplantation Date: 1998-04-27 Impact factor: 4.939
Authors: Markus J Barten; Teun van Gelder; Jan F Gummert; Katrin Boeke; Randi Shorthouse; Margaret E Billingham; Randall E Morris Journal: Am J Transplant Date: 2002-09 Impact factor: 8.086
Authors: Markus J Barten; Stefan Dhein; Hubert Chang; Hartmuth B Bittner; Attila Tarnok; Axel Rahmel; Friederich W Mohr; Jan F Gummert Journal: J Immunol Methods Date: 2003-12 Impact factor: 2.303
Authors: M Brunet; J M Campistol; O Millán; E Vidal; N Esforzado; I Rojo; O Jiménez; F Oppenheimer; J Corbella; J Martorell Journal: Int Immunopharmacol Date: 2003-07 Impact factor: 4.932
Authors: Josep M Grinyó; Josep M Cruzado; Olga Millán; Anna Caldés; Isabel Sabaté; Salvador Gil-Vernet; Daniel Serón; Mercé Brunet; Josep M Campistol; Joan Torras; Jaume Martorell Journal: Transplantation Date: 2004-11-15 Impact factor: 4.939
Authors: C Riggs; T Archer; C Fellman; A S Figueiredo; J Follows; J Stokes; R Wills; A Mackin; C Bulla Journal: Vet Immunol Immunopathol Date: 2013-12-15 Impact factor: 2.046
Authors: Sonny C Hsiao; Betty J Shum; Hiroaki Onoe; Erik S Douglas; Zev J Gartner; Richard A Mathies; Carolyn R Bertozzi; Matthew B Francis Journal: Langmuir Date: 2009-06-16 Impact factor: 3.882
Authors: Maja-Theresa Dieterlen; Hartmuth B Bittner; Attila Tarnok; Jens Garbade; Stefan Dhein; Friedrich W Mohr; Markus J Barten Journal: Surg Res Pract Date: 2014-02-06
Authors: Michael Klotsman; Sebastien Coquery; Gayatri Sathyan; Vatsala Naageshwaran; Paddy Shivanand; Amanda J Fairchild; Oliver A Garden; Wayne H Anderson Journal: Front Vet Sci Date: 2021-01-28
Authors: F Boix; I Legaz; A Minhas; R Alfaro; V Jiménez-Coll; A Mrowiec; H Martínez-Banaclocha; J A Galián; C Botella; M R Moya-Quiles; F Sanchez-Bueno; R Robles; J de la Peña-Moral; P Ramirez; J A Pons; A Minguela; M Muro Journal: Clin Exp Immunol Date: 2020-10-29 Impact factor: 4.330